Syndax Pharmaceuticals, Inc. (SNDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNDX POWR Grades
- Stability is the dimension where SNDX ranks best; there it ranks ahead of 35.85% of US stocks.
- The strongest trend for SNDX is in Momentum, which has been heading down over the past 31 weeks.
- SNDX ranks lowest in Growth; there it ranks in the 4th percentile.
SNDX Stock Summary
- Syndax Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 8.47% of US listed stocks.
- SNDX's price/sales ratio is 568.1; that's higher than the P/S ratio of 98.55% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SNDX comes in at -29.07% -- higher than that of only 9.11% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Syndax Pharmaceuticals Inc are VXRT, SVRA, ATHX, CAPR, and AIM.
- SNDX's SEC filings can be seen here. And to visit Syndax Pharmaceuticals Inc's official web site, go to www.syndax.com.
SNDX Price Target
For more insight on analysts targets of SNDX, see our SNDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $29.60 | Average Broker Recommendation | 1.42 (Moderate Buy) |
SNDX Stock Price Chart Interactive Chart >
SNDX Price/Volume Stats
| Current price | $18.76 | 52-week high | $27.85 |
| Prev. close | $19.00 | 52-week low | $13.02 |
| Day low | $18.55 | Volume | 305,100 |
| Day high | $19.26 | Avg. volume | 767,535 |
| 50-day MA | $18.31 | Dividend yield | N/A |
| 200-day MA | $20.06 | Market Cap | 905.15M |
Syndax Pharmaceuticals, Inc. (SNDX) Company Bio
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company was founded in 2005 and is based in Waltham, Massachusetts.
Latest SNDX News From Around the Web
Below are the latest news stories about Syndax Pharmaceuticals Inc that investors may wish to consider to help them evaluate SNDX as an investment opportunity.
Buy These 2 Stocks Before They Jump Over 60%, Says AnalystWe’re in interesting times, there’s no doubt about that. The COVID crisis is receding, the economic reopening is proceeding apace – but there are inflationary worries. The Biden Administration is committed to a heavy spending program, including generous extended unemployment benefits – which in some cases can exceed wages. As a result, the labor market is apparently stuck, running in low gear and prompting some concern that the recovery may not gain traction. Taking a macro view of the economic |
Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare ConferenceSyndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 2:10 p.m. ET. |
Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation SummitSyndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, 2021 at 12:00 p.m. ET. |
Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia TrialSyndax Pharmaceuticals Inc (NASDAQ: SNDX ), in its Q1 earnings , also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2 AUGMENT-101 trial evaluating SNDX-5613 in patients with MLLr and NPM1c mutant relapsed/refractory (R/R) acute leukemias. The new data showed that two prior responders have improved from a complete response with incomplete platelet recovery (CRp) to a complete response (CR) with no evidence of minimal residual disease (MRD) With the addition of these two patients, a … Full story available on Benzinga.com |
Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2021. In addition, the Company provided a clinical and business update. |
SNDX Price Returns
| 1-mo | 3.59% |
| 3-mo | -18.11% |
| 6-mo | -26.08% |
| 1-year | 21.03% |
| 3-year | 126.84% |
| 5-year | 44.53% |
| YTD | -15.65% |
| 2020 | 153.30% |
| 2019 | 97.30% |
| 2018 | -49.20% |
| 2017 | 22.18% |
| 2016 | N/A |
Continue Researching SNDX
Here are a few links from around the web to help you further your research on Syndax Pharmaceuticals Inc's stock as an investment opportunity:Syndax Pharmaceuticals Inc (SNDX) Stock Price | Nasdaq
Syndax Pharmaceuticals Inc (SNDX) Stock Quote, History and News - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...